Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.

Metabolites are the end products of cellular regulatory processes, and their levels can be regarded as the ultimate response of biological systems to genetic or environmental changes. We have used a metabolite profiling approach to test the hypothesis that quantitative signatures of primary metabolites can be used to characterize molecular changes in ovarian tumor tissues. Sixty-six invasive ovarian carcinomas and nine borderline tumors of the ovary were analyzed by gas chromatography/time-of-flight mass spectrometry (GC-TOF MS) using a novel contamination-free injector system. After automated mass spectral deconvolution, 291 metabolites were detected, of which 114 (39.1%) were annotated as known compounds. By t test statistics with P < 0.01, 51 metabolites were significantly different between borderline tumors and carcinomas, with a false discovery rate of 7.8%, estimated with repeated permutation analysis. Principal component analysis (PCA) revealed four principal components that were significantly different between both groups, with the highest significance found for the second component (P = 0.00000009). PCA as well as additional supervised predictive models allowed a separation of 88% of the borderline tumors from the carcinomas. Our study shows for the first time that large-scale metabolic profiling using GC-TOF MS is suitable for analysis of fresh frozen human tumor samples, and that there is a consistent and significant change in primary metabolism of ovarian tumors, which can be detected using multivariate statistical approaches. We conclude that metabolomics is a promising high-throughput, automated approach in addition to functional genomics and proteomics for analyses of molecular changes in malignant tumors.

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  Nigel W. Hardy,et al.  Hierarchical metabolomics demonstrates substantial compositional similarity between genetically modified and conventional potato crops. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Cor J. Veenman,et al.  A protocol for building and evaluating predictors of disease state based on microarray data , 2005, Bioinform..

[4]  Werner Welthagen,et al.  Statistical methods for comparing comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry results: metabolomic analysis of mouse tissue extracts. , 2005, Journal of chromatography. A.

[5]  Oliver Fiehn,et al.  Metabolic profiling of laser microdissected vascular bundles of Arabidopsis thaliana , 2005, Plant Methods.

[6]  Steven Mennerick,et al.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Werner Welthagen,et al.  Comprehensive two-dimensional gas chromatography–time-of-flight mass spectrometry (GC × GC-TOF) for high resolution metabolomics: biomarker discovery on spleen tissue extracts of obese NZO compared to lean C57BL/6 mice , 2005, Metabolomics.

[8]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[9]  W. R. Hart Borderline epithelial tumors of the ovary , 2005, Modern Pathology.

[10]  Stefan Michiels,et al.  Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.

[11]  E. Petricoin,et al.  Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy , 2005, Bioscience reports.

[12]  Jalid Sehouli,et al.  Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential , 2005, Oncogene.

[13]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[14]  Joachim Selbig,et al.  Metabolite fingerprinting: detecting biological features by independent component analysis , 2004, Bioinform..

[15]  Kazuki Saito,et al.  Potential of metabolomics as a functional genomics tool. , 2004, Trends in plant science.

[16]  R. Kurman,et al.  Borderline ovarian tumors: key points and workshop summary. , 2004, Human pathology.

[17]  D. Inzé,et al.  Connecting genes to metabolites by a systems biology approach. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Hirai,et al.  Integration of transcriptomics and metabolomics for understanding of global responses to nutritional stresses in Arabidopsis thaliana. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[20]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[21]  O. Fiehn,et al.  Process for the integrated extraction, identification and quantification of metabolites, proteins and RNA to reveal their co‐regulation in biochemical networks , 2004, Proteomics.

[22]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[23]  T. Bathen,et al.  Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[24]  Olivier De Wever,et al.  Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.

[25]  R. Kauppinen,et al.  Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. , 2003, Cancer research.

[26]  D. Edwards,et al.  Statistical Analysis of Gene Expression Microarray Data , 2003 .

[27]  Sandrine Dudoit,et al.  Classification in microarray experiments , 2003 .

[28]  Christina Gloeckner,et al.  Modern Applied Statistics With S , 2003 .

[29]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[30]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[31]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[32]  John R Griffiths,et al.  Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. , 2002, Cancer research.

[33]  S. Oliver Functional genomics: lessons from yeast. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[34]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[35]  G. D. Guthrie,et al.  Urine GABA levels in ovarian cancer patients: elevated GABA in malignancy. , 2001, Cancer letters.

[36]  M. Fukumoto,et al.  Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  O. Fiehn,et al.  Metabolite profiling for plant functional genomics , 2000, Nature Biotechnology.

[38]  B. Sitter,et al.  Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. , 1999, Anticancer research.

[39]  S. Stein,et al.  Deconvolution gas chromatography/mass spectrometry of urinary organic acids--potential for pattern recognition and automated identification of metabolic disorders. , 1999, Rapid communications in mass spectrometry : RCM.

[40]  S. Sisenwine,et al.  Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. , 1999, Journal of chromatography. A.

[41]  K. Brindle,et al.  Induction of apoptosis in two mammalian cell lines results in increased levels of fructose‐1,6‐Bisphosphate and CDP‐choline as determined by 31P MRS , 1998, Magnetic resonance in medicine.

[42]  R. Kauppinen,et al.  Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. , 1998, Cancer research.

[43]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. , 1998, Gynecologic oncology.

[44]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[45]  F. Oesch,et al.  Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer , 1997 .

[46]  F. Oesch,et al.  Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. , 1997, Gynecologic oncology.

[47]  Mark Noble,et al.  Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours , 1995, NMR in biomedicine.

[48]  S. Williams,et al.  Cell type-specific fingerprinting of meningioma and meningeal cells by proton nuclear magnetic resonance spectroscopy. , 1995, Cancer research.

[49]  K. Tanaka,et al.  Gas-chromatographic method of analysis for urinary organic acids. II. Description of the procedure, and its application to diagnosis of patients with organic acidurias. , 1980, Clinical chemistry.

[50]  K. Tanaka,et al.  Gas-chromatographic method of analysis for urinary organic acids. I. Retention indices of 155 metabolically important compounds. , 1980, Clinical chemistry.